a fact that the pubertal spurt may improve not only auxology but also the underlying jejunal pathology. Therefore it is very difficult to analyse auxology of children in such a period. The number of the investigated patients is so impressive that it would be possible to analyse separately those patients who had adhered to a gluten free diet and those who had not complied with this regime. 
In vitro' data for other drugs is not readily available but children with ataxia telangiectasia have been reported to tolerate systemic methotrexate/6-mercaptopurine treatment in normal doses.4 It would be interesting, in the Newcastle case, to know the temporal distribution of the reported 'gaps and reductions' in methotrexate/6-mercaptopurine treatment. If most occurred during the first year of treatment, rather than the second, it may be that lingering radiation treatment induced DNA damage to bone marrow in the craniocervical area, rather than chemotherapy, was blameworthy. A possible increase of vinca-alkaloid induced neurotoxicity has been noted in one report, but is not mentioned in others.4 This report, which includes a literature review, also contains the specific statement 'No adverse effects from monthly intra-thecal methotrexate were noted in our patients'.
Although ataxia telangiectasia is itself very rare it is relatively more common in the selected group of children who develop acute lymphoblastic leukaemia or malignant lymphoma. While it is clear that radiation treatment must be given in reduced dosage-if at all-to patients with ataxia telangiectasia,2 and though vincristine is still 'sub judice' it would be unfortunate if intrathecal or systemic methotrexate (or systemic 6-mercaptopurine, asparaginase, or anthracycline) doses were automatically scaled down or omitted. For children with ataxia telangiectasia and acute lymphoblastic leukaemia or lymphoma, the likely outcome would be an increased relapse rate. In many countries children's cancer treatment is now coordinated by national children's cancer study groups. Specific treatment recommendations for children with ataxia telangiectasia and malignancy are needed and could be publicised by thesegroups (in this country, the UKCCSG).
Incidentally, the terms 'central nervous system prophylaxis' and 'maintenance treatment', as used in the article, are inaccurate and archaic and should be abandoned.5 'Central nervous system-directed treatment' and 'continuing treatment' are preferred alternatives.
